Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Research & Development (2017 - 2025)

BioCorRx (BICX) has disclosed Research & Development for 9 consecutive years, with $305516.0 as the latest value for Q4 2025.

  • Quarterly Research & Development rose 12.1% to $305516.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 million through Dec 2025, up 19.29% year-over-year, with the annual reading at $1.8 million for FY2025, 19.29% up from the prior year.
  • Research & Development hit $305516.0 in Q4 2025 for BioCorRx, down from $1.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.0 million in Q3 2025 to a low of $123262.0 in Q2 2021.
  • Historically, Research & Development has averaged $360413.0 across 5 years, with a median of $291911.0 in 2023.
  • Biggest five-year swings in Research & Development: crashed 90.84% in 2021 and later soared 210.68% in 2022.
  • Year by year, Research & Development stood at $234423.0 in 2021, then surged by 128.69% to $536104.0 in 2022, then crashed by 76.07% to $128295.0 in 2023, then surged by 112.43% to $272543.0 in 2024, then increased by 12.1% to $305516.0 in 2025.
  • Business Quant data shows Research & Development for BICX at $305516.0 in Q4 2025, $1.0 million in Q3 2025, and $296860.0 in Q2 2025.